key: cord-1050367-cobre86c
authors: Liang, Xiao; Xiao, Jun; Li, Xuzichao; Wen, Yanan; Che, Xing; Ma, Yongjian; Zhang, Xingyan; Zhang, Yi; Jian, Deng; Wang, Peihui; Xuan, Chenghao; Yu, Guimei; Li, Long; Zhang, Heng
title: Structural insights into the viral proteins binding by TRIM7 reveal a general C-terminal glutamine recognition mechanism
date: 2022-03-24
journal: bioRxiv
DOI: 10.1101/2022.03.24.485560
sha: 54f8ad9b482d2342d5e882c8374d0a3a43041c29
doc_id: 1050367
cord_uid: cobre86c

The E3 ligase TRIM7 has emerged as a critical player in viral infection and pathogenesis. A recent study found that TRIM7 inhibits human enteroviruses through ubiquitination and proteasomal degradation of viral 2BC protein by targeting the 2C moiety of 2BC protein. Here, we report the crystal structures of TRIM7 in complex with 2C, where the C-terminal region of 2C is inserted into a positively charged groove of the TRIM7 PRY-SPRY domain. Structure-guided biochemical studies revealed the C-terminus glutamine residue of 2C as the primary determinant for TRIM7 binding. Such a glutamine-end motif binding mechanism can be successfully extended to other substrates of TRIM7. More importantly, leveraged by this finding, we were able to identify norovirus and SARS-CoV-2 proteins, and physiological proteins, as new TRIM7 substrates. We further show that TRIM7 may function as a restriction factor to promote the degradation of the viral proteins of norovirus and SARS-CoV-2, thereby restoring the Type I interferon immune response and inhibiting viral infection. Several crystal structures of TRIM7 in complex with SARS-CoV-2 proteins are also determined, and a conserved C-terminus glutamine-specific interaction is observed. These findings unveil a common recognition mode by TRIM7, providing the foundation for further mechanistic characterization of antiviral and cellular functions of TRIM7.

The tripartite motif (TRIM) family proteins play essential roles in a plethora of cellular processes including signal transduction, oncogenesis, cell death and antimicrobial responses 1, 2 .

TRIM proteins, belonging to the RING E3 ligase family, are characterized by the conserved RBCC domain architecture consisting of the RING (R), one or two B-boxes (B) and the coiledcoil (CC) domains, and a variable C-terminal domain (CTD) 3 . The RING domain recruits ubiquitin-loaded E2 and catalyzes the conjugation of ubiquitin to substrates, while B-box and coiled-coil domains mainly play regulatory roles. The CTD usually confers substrate specificity.

More than ten distinct types of CTD have been identified, among which is the PRY-SPRY domain present only in vertebrates 4, 5 .

As a member of the TRIM family, TRIM7 is featured with one B-box domain in the RBCC architecture and a C-terminal PRY-SPRY domain. TRIM7 is implicated in multiple critical cellular processes, such as glycogen biosynthesis and oncogenic signaling pathways including c-Jun/AP1 activation and the DUSP6/p38 pathway through different substrates [6] [7] [8] . Notably, TRIM7 is also emerging as a crucial player in viral pathogenesis. For example, a recent study has identified human TRIM7 as an intrinsic antiviral effector against human enteroviruses such as coxsackievirus B3 (CVB3) 9 , which are positive-sense single-stranded RNA (+ssRNA) viruses.

TRIM7-mediated ubiquitination and subsequent degradation of viral 2BC protein are implicated to inhibit viral infection. The non-structural protein 2C, which is derived from proteolysis of the precursor 2BC protein, functions as an ATPase/helicase to regulate viral RNA replication.

TRIM7 recognizes the C-terminal region of 2C via PRY-SPRY domain, leading to ubiquitination and proteasomal degradation of viral 2BC protein but not 2C protein, thereby suppressing enterovirus replication 9 . In addition, a genome-wide CRISPR screen revealed that TRIM7 also restricts norovirus infection in a ubiquitination-dependent manner through yet unknown substrates 10 .

To elucidate the molecular mechanism of substrate recognition by TRIM7, we have determined multiple crystal structures of TRIM7 in complex with CVB3 2C protein. The structural studies combined with biochemical characterization allow us to propose a glutamineend motif binding mechanism, where TRIM7 recognizes 2C mainly through C-terminus glutamine-specific interactions. Strikingly, this binding mode is found to be preserved for other targets. More importantly, leveraged by this new knowledge, we were able to predict and identify new viral targets in noroviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which are both +ssRNA viruses as with enteroviruses. Our findings not only unveil a general substrate binding principle for TRIM7, but also demonstrate a prevalent and versatile role of TRIM7 in +ssRNA virus infection and physiological processes such as tumorigenesis, potentially opening new avenues for therapeutic intervention in viral diseases and cancers.

Human TRIM7 restricts CVB3 enterovirus infection, by recognizing and degrading the viral protein 2BC, which could be further proteolytically processed into 2B and 2C proteins 9 . The physical association was indicated to primarily occur between the PRY-SPRY domain of TRIM7 (hereinafter termed as TRIM7 unless otherwise indicated) and the 2C moiety of 2BC, especially the C-terminal region of 2C (117-329 aa, denoted as 2C unless otherwise stated) 9 (Fig. 1a) . To further characterize the TRIM7-2C interaction, we purified the proteins and examined their binding using isothermal titration calorimetry (ITC). Indeed, TRIM7 tightly associated with 2C with a dissociation constant (K D ) of ~ 6 M (Fig. 1b) . By contrast, no obvious binding was observed after truncating the last 11 residues of 2C (117-318 aa), consistent with the previous pull-down assay results 9 . Similarly, TRIM7 was stoichiometrically co-eluted with 2C but not the C-terminus deleted 2C protein in gel filtration (Figs. 1c and S1a-c). In line with these results, the C-terminus derived peptide fragment displayed a binding affinity of ~ 3 M toward TRIM7 ( Fig.   S1d-e) , comparable to that of 2C protein, demonstrating a dominant role of this C-terminal motif in binding of TRIM7.

Apart from the type B enterovirus CVB3, TRIM7 was also reported to inhibit other human enteroviruses such as enterovirus 71 (EV71, type A), poliovirus (PV, type C) and enterovirus D68 (EVD68, type D) 9 . Sequence analysis of these 2C proteins revealed a highly conserved Cterminus ( Fig. S1d) , indicating that TRIM7 may use a general binding mode for different 2C proteins of human enteroviruses. This is supported by the results that TRIM7 binds to the Ctermini of different 2C proteins with similar binding affinities (3-9 M) (Fig. S1e) .

Next, we set out to further elucidate the structural basis of TRIM7-2C complex association.

Although extensive crystallization trials of TRIM7-2C complex failed, we were able to crystallize and determine multiple structures of TRIM7 (338-511 aa, PRY-SPRY domain) in complex with CVB3 2C-derived peptides (319-329 aa) at high resolutions (1.1-1.6 Å) ( Table   S1 ). Atomic protein models were built unambiguously for TRIM7 and the last four to ten residues of 2C (Figs. 1d and S2a). All the solved structures with different space groups are nearly identical (Fig. S2b) , excluding the possibility of artifacts caused by crystal packing.

TRIM7 exhibits a typical PRY-SPRY domain fold 4 , composed of two antiparallel -sheets connected by loops of variable lengths (Fig. 1d) . These two -sheets, -sheet A and -sheet B, pack against each other in a twisted -sandwich configuration with a concave surface at one side and a convex surface for the other side. The -sheet A and loops 3 and 6 form a positively charged groove to accommodate 2C (Fig. 1e) . Interestingly, this is different from a previously predicted binding mode between TRIM7 and glycogenin-1 (GN1) 11 . The binding affinity between TRIM7 and 2C was reduced by ~ 3-fold in a higher salt binding buffer, demonstrating that the polar contacts contribute to their physical association (Fig. S2c) . Mapping of the evolutionary sequence conservation to TRIM7 structure revealed an invariant binding pocket ( Fig. S2d) , suggesting a conserved 2C recognition mode across TRIM7 orthologs.

In the present structure, 2C displays a helical structure that inserts into the binding groove on the concave side of TRIM7. Specifically, the C-terminus Gln329 (termed as position -1) of 2C situated at the bottom of the binding pocket is involved in substantial interactions with TRIM7 (Fig. 2a) . The side-chains of Asn383, Arg385 and Ser499 from TRIM7 make polar interactions with the carboxyl group of Gln329. On the other side, the amide moiety of Gln329 is buttressed by hydrogen bonds to the main-chains of Gly408 and Ser499, as well as the sidechains of Gln436 and Ser499 from TRIM7. The side-chain of Gln329 is further bracketed by Phe426 and Cys501 through hydrophobic interactions.

The carbonyl group of Phe328 (position -2) of 2C engages in hydrogen bonds with Thr384 of TRIM7 (Fig. 2b) , while its aromatic ring is further stabilized by hydrophobic contacts with Thr382 and Leu423. Leu327 (position -3) of 2C is anchored in place mainly through the hydrophobic interaction with Leu423 of TRIM7. Nevertheless, few contacts were observed beyond the last three residues of 2C (Fig. 2c) .

To explore the importance of the observed interactions, we introduced point mutations into TRIM7 and measured their binding affinities. Replacement of the Gln329-interacting residues with alanine, including Asn383, Arg385, Phe426, Gln436, Ser499 and Cys501, significantly reduced or abolished 2C binding (Fig. 2d) . Similarly, the interaction of TRIM7 with 2C was disrupted when mutating the Phe328-interacting residues (Thr382, Thr384 and Leu423) (Fig. 2e) .

However, substitution of other residues (such as Asn438 and Ser502) in the binding groove with alanine had no or very little effect on the binding affinity (Fig. 2e) .

To further discern the residues of 2C crucial for TRIM7 binding, we generated point mutations on 2C for binding studies. Not surprisingly, both the Q329A and F328A mutations significantly impaired the binding (Fig. 2f) . Nonetheless, alanine substitutions of Leu327-Thr322 had no impact on binding. These results demonstrated the critical role of the last two residues of 2C, Gln329 and Phe328, in binding of TRIM7.

As aforementioned, the last two or three residues in 2C seem to be the determinant for TRIM7 binding. To further understand the binding preference of TRIM7, we generated a series of 2C mutants on the last three positions and examined their binding. Gln329 at position -1 fits snugly into the binding pocket (Fig. 3a) . Substitution of Gln329 with bulkier residues, such as tyrosine, arginine and methionine, that is expected to have steric clashes, exhibited no binding to TRIM7 (Fig. 3b) . Likewise, replacement of Gln329 with smaller residues (alanine, threonine, asparagine and valine) disrupted the TRIM7 binding, likely due to loss of the amide groupmediated interactions with Gln436 and Ser499. Notably, mutation of Gln329 to glutamate with a highly similar chemical structure also abrogated the binding. Molecular dynamics (MD) analysis revealed that Q329E mutation affects the solvation and interrupts hydrogen-bonding with TRIM7 (Figs. 3c and S3a and Table S2 ), which could explain the profoundly weakened binding.

The free C-terminal carboxyl group is also critical for TRIM7 binding, which is supported by the finding that no detectable binding was observed in the presence of the C-terminal amidation modification (Fig. 3b) . Collectively, these results suggest that a glutamine residue at position -1 is indispensable and irreplaceable for TRIM7 binding.

Phe328 at position -2 rests against the rim of the pocket with its aromatic ring surrounded by the hydrophobic side-chains of Leu423, Thr382 and Thr384 (Fig. 3d) . Replacement of Phe328 with smaller residues (alanine, threonine, valine, asparagine, glutamate), with the potential to lose the phenyl group-mediated hydrophobic interaction, substantially reduced TRIM7 binding (Figs. 2f and 3e) . Arginine substitution of Phe328 would also weaken the interaction due to the electrostatic repulsion with Arg354 of TRIM7, which agrees with our finding that F328R mutation significantly diminished the binding of TRIM7. However, substitution of Phe328 with bulkier residues such as methionine and tyrosine would be better tolerated. Indeed, F328M had a similar binding affinity to TRIM7 as WT (Fig. 3e) . Leu327 at position -3 protrudes outwards from the pocket (Fig. 3d) , forming loose interactions with the binding surface of TRIM7. Different types of amino acid substitutions at position -3 were all tolerated (Fig. S3b) . Taken together, our results demonstrate that TRIM7 not only specifically recognizes glutamine at position -1, but also has a preference for bulky hydrophobic residues at position -2. This observation could explain why 2C protein from non-human enterovirus mengovirus (MenV), which harbors an alanine residue at the position equivalent to Phe328 in CVB3 2C protein, fails to interact with TRIM7 9 . Mutating alanine to phenylalanine in 2C of MenV was sufficient to restore the TRIM7 binding (Fig. 3f) , highlighting the importance of the secondary determinant involving -2 position.

TRIM7 was recently reported to inhibit the replication of norovirus 10 . However, the target of TRIM7 remains poorly understood. Referring to the observed glutamine-end motif binding rule, we therefore examined the sequence information of norovirus proteins. Several viral proteins, such as capsid protein VP1, p48, NTPase and the 3C-like protease, were found bearing the TRIM7 recognition motif, among which NTPase was found most conserved in different genogroups (GI-GV) (Fig. 4a) . We therefore focused our study on NTPase.

ITC measurement showed that the NTPase C-terminal peptide fragments from both human (GI) and murine (GV) noroviruses directly interact with TRIM7 with K D values of ~ 6-10 µM ( Fig. 4b) , while alanine replacement of the C-terminus glutamine in either GI or GV NTPase abolished the TRIM7 binding (Fig. 4c) . Consistently, WT NTPase protein derived from human norovirus, but not the C-terminal alanine-substituted NTPase protein, co-immunoprecipitated with TRIM7 (Fig. 4d) . These results demonstrate that TRIM7 indeed can target norovirus NTPase protein using the glutamine-end motif binding mechanism both in vitro and in vivo.

We next asked whether TRIM7 could ubiquitinate and degrade NTPase. Either WT TRIM7 or ligase dead TRIM7 (C29A/C32A) was co-transfected with NTPase from human norovirus and ubiquitin into the HEK293T cells. As expected, WT TRIM7, but not the ligase dead mutant, robustly ubiquitinated NTPase (Fig. 4e) . Furthermore, expression of WT TRIM7 triggered the degradation of NTPase, whereas the degradation was inhibited by treatment with the proteasome inhibitor MG132 but not the DMSO (Fig. 4f) , implicating the 26S proteasome-dependent degradation. The NTPase protein possesses fundamental enzymatic activities required for viral replication 12 . It has been demonstrated that norovirus NTPase impairs the Type I interferon-β (IFN-β) expression 13 . We next determined whether TRIM7 interferes with this NTPasemediated suppression. To this end, NTPase expression plasmid was co-transfected with the IFNβ luciferase reporter plasmid and the vectors expressing RIG-I CARD and TRIM7. The expression of NTPase inhibited the IFN-β production, whereas WT TRIM7 restored the expression level of IFN-β (Fig. 4g) , suggesting a restriction role of TRIM7 in norovirus infection.

However, the ligase dead TRIM7 mutant had no obvious effect on IFN-β expression. Similarly, the NTPase-mediated suppression of IFN-β was not affected regardless of the presence or absence of WT TRIM7 when the C-terminus glutamine of NTPase was mutated to alanine (Fig.   4g) , further demonstrating the importance of C-terminal glutamine-specific recognition. Hence, it is likely that TRIM7 may inhibit norovirus infection through degradation of the NTPase protein.

As TRIM7 restricts the infection of human enterovirus and norovirus, both of which are +ssRNA viruses, it raises an interesting question whether TRIM7 could function as a broadspectrum regulator in +ssRNA virus infection. We therefore attempted to explore whether another +ssRNA virus, SARS-CoV-2, could be targeted by TRIM7 based on the identified substrate recognition rule. Sequence analysis was performed for proteins encoded by SARS-CoV-2 genome, surprisingly revealing that most of the nonstructural proteins (NSP) including NSP4-10, NSP12-15, and the structural membrane (M) protein have the glutamine-end motif ( Fig. 5a) . ITC experiments were then performed to evaluate their association with TRIM7. As revealed, binding was detected for all the measured peptides derived from the C-termini of these candidates (Fig. 5b) . Supporting our observation, a recent proteomics study also shows that TRIM7 interacts with the M protein of SARS-CoV-2 14 . To further confirm the interaction, fulllength NSP5 protein was purified, which consistently was found bound with TRIM7 (Fig. 5c) .

These were in agreement with the co-IP experiment, where WT NSP5 and NSP8, but not the alanine mutations at the C-terminal glutamine, were detected in the immunoprecipitated samples of TRIM7 (Fig. S4a) . Furthermore, expression of TRIM7 triggered the ubiquitination and proteasomal degradation of NSP5 and NSP8 (Figs. 5d-f) . Together, these results demonstrate that TRIM7 could target a large array of SARS-CoV-2 viral proteins, which may modulate the SARS-CoV-2 infection and pathogenesis. We further determined the crystal structures of TRIM7 in complex with NSP5-, NSP8-and NSP12-derived peptides at high resolutions (1.2-1.4 Å) (Figs.

4g-h and S4b) (Table S3) . Although the C-terminal sequences among these three NSP proteins are divergent (Fig. 5a) , their binding modes are similar to that of 2C in TRIM7-2C complex, suggesting a conserved C-terminal glutamine recognition mechanism.

We next sought to characterize the role of TRIM7 in SARS-CoV-2 viral infection. Given that SARS-CoV-2 proteins could antagonize IFN signaling 15-20 , we co-transfected HEK293T cells with the plasmid encoding individual SARS-CoV-2 NSP proteins, a IFN-β luciferase reporter plasmid and a RIG-I CARD expression plasmid. Consistent with recent studies, we observed that expression of SARS-CoV-2 viral proteins including NSP5, NSP6 and NSP8 significantly suppressed IFN-β production (Fig. S4c) , suggesting that these NSP proteins may inhibit IFN signaling to evade host immune response. However, IFN-β expression was rescued in the presence of WT TRIM7 but not the ligase dead mutant, indicative of TRIM7 as a restriction factor in viral infection (Fig. 5i) . We next explored how these NSP proteins affect IFN response. TBK1 phosphorylation, a key event for IFN signaling, was impaired when expressing NSP5 or NSP8 protein (Fig. S4d-e) . As expected, WT TRIM7, but not the catalytic dead TRIM7 mutant, compromised the inhibition effects of NSP5 and NSP8 proteins. To reconcile the glutamine-end binding mode, we also introduced mutation into the C-terminal glutamine residues in NSP5 and NSP8. These mutations blocked the IFN-β production and TBK1 phosphorylation similar to the WT NSP5 and NSP8 (Figs. 5i and S4d-e) . Nonetheless, TRIM7 failed to restore IFN response in the presence of these NSP mutations. Together, our data demonstrate that TRIM7 may function as a restriction factor in SARS-CoV-2 infection through glutamine-end specific recognition mode.

TRIM7 also regulates diverse human proteins to exert its cellular functions. We next asked whether the same recognition mode of viral proteins by TRIM7 is also adopted by the cellular targets. Multiple cellular proteins that have been previously reported as putative targets of TRIM7 were explored, including BRMS1, DUSP6, GN1, RACO-1 and STING 7,8,21-23 . Indeed, TRIM7 was able to directly interact with the C-terminal peptide fragments of GN1 (~ 8 µM ) and RACO-1 (~ 10 µM ) containing tolerable glutamine-end motifs (Fig. S5a) . Mutation of the Cterminus glutamine in RACO-1 completely abolished TRIM7 binding (data not shown).

In contrast, the peptide or protein fragments, which are derived from the C-termini of BRMS1, DUSP6 and STING without glutamine-end, exhibited no obvious binding toward TRIM7 (Fig. S5b) . The potential explanation is that these proteins could possibly interact with TRIM7 either through additional binding partners or a different interface 24, 25 . Taken together, these results indicate that the glutamine-end motif binding mechanism is a common, albeit potentially not the only, target recognition strategy of TRIM7 for both human and viral proteins.

TRIM7 has emerged as an essential regulator of cancer development 7, 8, 21, 26, 27 . Several cancer-related TRIM7 somatic mutations in the COSMIC database (N383S, R385C, L423P, S502F) 28 , which are located in the substrate binding pocket (Figs. 2a-c and S5c) , failed to bind the substrate in our ITC experiments (Fig. S5d) . It will be interesting to further investigate these mutations in the context of oncogenesis.

TRIM7, a RING type E3 ligase, is implicated in viral infection as well as oncogenesis [7] [8] [9] [10] 21 .

However, the detailed mechanism by which TRIM7 recognizes substrate is unclear. In this study, we structurally and biochemically characterized the interaction between TRIM7 and different viral substrates, including protein 2C of CVB3 enterovirus, and non-structural proteins of SARS-CoV-2, revealing a common target binding mode, thereby enabling the identification and discovery of new substrates, such as viral proteins in positive sense single-stranded RNA (+ssRNA) viruses.

The C-terminus Gln329 of 2C protein (position -1) is buried in the binding pocket of TRIM7, establishing extensive polar and hydrophobic contacts (Fig. 2a) . Our data demonstrate the glutamine-end as the primary determinant for TRIM7 binding. TRIM7 also displays a strong preference for bulky hydrophobic amino acids at position -2. This explains why the MenV 2C protein terminating with glutamine (alanine at position -2) fails to interact with TRIM7 9 (Fig.   3f) . Therefore, TRIM7 has best preference for substrate with the C-terminal φQ (φ denotes bulky hydrophobic residue) motif. However, the other positions of substrate may also affect the TRIM7 binding, especially in the cellular context. It is possible that TRIM7 might be able to bind the proteins harboring the unfavorable C-terminal motif such as AQ under the physiological conditions, albeit with low binding affinity in our assay. Future studies would be required to systematically investigate the TRIM7 binding in the cellular context.

TRIM7 was reported to suppress human enterovirus replication by degrading viral protein 2BC but not 2C, although the 2C part in 2BC is responsible for TRIM7 binding 9 . It is likely that a precise orientation of substrate would be required for the ubiquitin deposition 29 . As previously reported, alanine mutation of Thr323 at 2C would confer resistance to TRIM7 9 . In our structure, the hydroxyl group of Thr323 is hydrogen bonded to Asn438 of TRIM7 (Fig. 2c) . However, mutations of Thr323 including T323A, T323G, T323S and T323I had little effect on the binding (Fig. S6) . One proposed possibility is that these variants would alter the plasticity and enzymatic activity of 2C to gain a fitness advantage in vivo 9 . The N-terminal domain induces the hexamerization of 2C. Alternatively, these mutations may affect the binding in the context of full-length rather than the N-terminus deleted 2C protein.

We also identified and demonstrated the NTPase protein, which harbors a highly conserved glutamine-end across norovirus genogroups, as a substrate of TRIM7. Ubiquitination and proteasomal degradation of norovirus NTPase could potentially suppress the enzymatic activities necessary for viral replication 12 , and counteract its negative effect on IFN-β production 13 (Fig.   4g) , which thereby inhibits norovirus infection 10 . In addition, the 3C-like protease possessing a C-terminus glutamine residue in murine norovirus but not in other noroviruses could be an extra, murine norovirus-specific TRIM7 target (Fig. 4b) .

Our study further indicates TRIM7 as a potentially essential restriction factor for SARS-CoV-2 infection. Through the same glutamine-end motif recognition mechanism, TRIM7 targets the structural protein M, nonstructural proteins NSP4-10 and NSP12-15, which are all essential proteins for SARS-CoV-2 viral replication 30 . Ubiquitination and subsequent degradation of these NSP proteins by TRIM7 could affect their functions such as suppression of immune signaling ( Fig. 5d-f,i) . Intriguingly, TRIM7 could readily target all the components of the replication-transcription complex composed of NSP7, 8, 12 and 13 31 (Fig. 5b) , which are promising targets for COVID19 disease treatment 32, 33 . It is therefore likely that the TRIM7triggered ubiquitination and proteasomal degradation, or sequestration of these components through binding could possibly lead to suppression of the SARS-CoV-2 replication. However, further studies will be needed to explore the relationship between TRIM7 and SARS-CoV-2

infection.

TRIM7 has also been reported to play a positive role in Toll-like receptor-mediated innate immune response that could be triggered by ssRNA virus infection 34 . Collectively, these findings imply a potentially prevalent role of TRIM7 E3 ligase in restricting +ssRNA virus infection. Interestingly, TRIM7 was also found involved in promoting Zika virus (+ssRNA) entry by ubiquitinating the viral envelope protein 35 , indicating potential functional versatility of TRIM7 in response to different +ssRNA virus infections.

The +ssRNA viral genomes generally encode polyproteins, which are proteolytically cleaved into individual structural and nonstructural viral proteins by viral proteases. The substrate cleavage specificity of these viral proteases therefore determines the C-terminal sequences of the mature viral proteins. The 3C or 3C-like proteases of human enterovirus, norovirus and SARS-CoV-2 virus show cleavage preference for the glutamine at the position P1 [36] [37] [38] [39] , releasing glutamine-terminated viral proteins, which explains the vulnerability of their mature viral proteins to TRIM7 targeting and inhibition. Examination of more viral proteases thus may further extend the spectrum of +ssRNA viruses targeted by TRIM7.

Several proteins have been reported as putative cellular substrates of TRIM7 [6] [7] [8] 21, 27 , among which direct binding was detected for those possessing the glutamine-end motif but not others.

One possible explanation is that TRIM7 may interact with bridging proteins to exert E3 ligase activity. Alternatively, other regions may be involved in substrate binding. Such a mechanism can be supported by the recent observations that the coiled-coil domain of TRIM7 is responsible for binding of MAVS protein 25 . As there are several thousands of human proteins terminated with glutamine, the recognition principle described here would enable the identification of more physiological targets of TRIM7.

The ubiquitin-proteasome system (UPS) controls protein stability through recognizing degradation signals, which is generally a motif of fewer than ten residues in the N-or C-terminus, namely N-or C-degrons, respectively 40 . Several classes of C-terminal degrons such as Arg/Cend, Glu/C-end, Gly/C-end and Ala/C-end have been discovered 41, 42 . The observed C-end glutamine rule by the TRIM7 E3 ligase in UPS may represent a new type of Gln/C-end degron pathway.

In summary, our study has elucidated a general binding principle for both viral and physiological substrates of TRIM7, which would guide further biological studies of TRIM7 functions and the development of antiviral and disease therapeutics.

DNA encoding TRIM7 (338-511 aa) and CVB3 2C (117-329 aa) protein were synthesized His-tagged TRIM7 was further purified using the Superdex 200 size exclusion column with a running buffer containing 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM DTT. TEV was used to remove the His-SUMO tag for 2C, which was further purified by ion-exchange chromatography using HiTrap Q column (Cytiva). Peak fractions were collected and concentrated for use.

We also generated a fusion construct in which 2C (319-329 aa) was C-terminally linked to TRIM7 (338-511aa) using a (GSA) 5 linker. The fusion protein was purified by the same protocol as above. DNA encoding peptides derived from the C-terminal last 10 residues of the norovirus and cellular proteins were cloned into the pET-His-GST vector (Addgene:29655) with an Nterminal GST tag. Proteins were purified using the GST affinity chromatography (Cytiva). The eluted proteins were further purified using the HiTrap Q column. Peak fractions were collected and concentrated for the ITC binding experiments. The plasmid encoding NSP5 was a gift from Dr. Jian Lei. Protein expression and purification was performed as previously described 43 .

Crystallization, data collection and structure determination TRIM7 was concentrated to ~16 mg/ml and incubated with synthesized peptides (Sangon Biotech) on ice for 30 min with a molar ratio of 1:2. The fusion protein was concentrated to ~15 mg/ml. Crystallization was performed using the sitting-drop vapor diffusion method at 18℃. The crystals were obtained by mixing 1 μl protein solution and 1 μl crystallization buffer. The Crystals were cryoprotected in the mother liquor supplemented with 20% glycerol before flash frozen in liquid nitrogen. X-ray diffraction datasets were collected at beamline BL18U1 of Shanghai Synchrotron Radiation Facility (SSRF) 44 . Structures were solved by molecular replacement using TRIM7 structure (PDB ID: 6UMA) as a searching model in CCP4I2 package 45 . Structures of bound peptides were manually constructed using the COOT program 46 . The refinement of structures was performed with PHENIX 47,48 and CCP4I2 45 . Statistics of data processing and structural refinement are listed in Table S1 and S3.

All the isothermal titration calorimetry (ITC) experiments were carried out in a buffer containing 25 mM Tris-HCl pH 8.0, 150 mM NaCl (unless otherwise stated) using a MicroCal PEAQ-ITC system (Malvern) at 25°C. A typical titration experiment involved 19 injections of protein or peptide substrate (300 μM to 2 mM) solution into the cell containing TRIM7 protein (20-50 μM).

Data was analyzed using MicroCal PEAQ-ITC analysis software.

Superdex 200 Increase 10/300 column (Cytiva) was used to carry out the gel-filtration assay.

TRIM7 and 2C proteins were incubated on ice for 30 min at a 3:1 molar ratio before subjected to the column pre-equilibrated with the running buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM DTT). Peak fractions were collected and analyzed using SDS-PAGE.

To understand the effect of the Q329E mutation to the TRIM7-2C complex, molecular dynamics (MD) simulation was performed. Amber FF14SB force field 49 was used for the wild type and Q329E complexes. Both complexes are solvated in TIP3P water so that the minimum distance between the box boundary and any atom in the complexes is 10 Å. As a result, 11182 and 11179 water molecules are added to the complex systems, correspondingly. Both systems follow the same simulation routine. The time step is 2 fs with the SHAKE algorithm 50 to fix the hydrogen atoms. The cutoff for calculating the electrostatic interaction is 8 Å. First, 3000 steps steepest descent followed by 2000 steps conjugate gradient minimization are performed. After that, additional 7000 steps steepest descent followed by 3000 steps conjugate gradient are performed without restraint. After the minimization, the system is heated up to 300 K within 20 ps. The system is then equilibrated in the NPT ensemble for 100 ps, followed by a further equilibration of 100 ps in NPT. The temperature is controlled at 300 K by Langevin dynamics. The pressure is controlled at 1 bar by isotropic Berendsen barostat. Both the temperature and pressure are regulated every 1 ps. The production MD simulation is carried out in a NPT ensemble with the same parameter settings. The ccptraj module was used for the analysis of trajectories 51 .

HA-tagged human TRIM7 was constructed by inserting into the pCMV-HA vector. Flag-tagged norovirus NTPase, SARS-CoV-2 NSP5 and NSP8 were cloned into the pCMW-Tag2B vector.

HEK293T cells were cultured in Dulbecco's modified eagle medium (DMEM, Gibco) supplemented with 10% fetal bovine serum, 2 mM glutamine and 100 U/ml penicillin/streptomycin at 5% CO2 at 37°C. Transfection was performed with polyethyleneimine (PEI). Cells cultured in 6-well plates were prepared in serum-free DMEM media. For each well, 3 µg DNA and 9 µg PEI were pre-incubated in 200 µL serum-free DMEM by vertexing for 15 min. The PEI/DNA mixture was then added into cells and incubated for 4 h at 37℃. Serum-free medium with DNA/PEI mixture was then replaced by the complete medium. Cells were then cultured for 24-48 h to express target proteins. 

HEK293T cells (1×104/well, 96-well white plate) stably expressed TRIM7/TRIM7-mut or EGFP were co-transfected with 20-80 ng of indicated expression plasmids or empty vector, and luciferase plasmid cocktail containing 10 ng of IFN-β-firefly-luc plasmid (IFN-β promoterdriven firefly luciferase plasmid) and 5 ng of pTracer-Renilla-luc plasmid (luciferase control plasmid). Cells were stimulated by co-transfection with 10 ng of pcDNA3-RIG-I (2CARD) plasmids, and empty pcDNA3 vector was used as unstimulated control. Lipofectamine 3000 reagent (Invitrogen, L3000001) was used to transfect these plasmids. 24 h post-transfection, the cells were assayed for dual-luciferase assay activities according to the manufacturer's instructions (Beyotime, RG088S).

HEK293T cells (1×105/well, 12-well plate) were co-transfected with TBK1-Myc-expressing plasmid, NSP5/NSP8-encoding plasmids and TRIM7-HA expression plasmid. 24 h posttransfection, western blot was used to analyze the cell lysates for S172-phosphorylated TBK1 (CST, D52C2), total TBK1 (anti-TBK1), and indicated protein.

For degradation studies, HEK293T cells (1×105/well, 12-well plate) were co-transfected with indicated expression plasmids encoding potential TRIM7 substrates, and increasing amounts of 

Shanghai Synchrotron Radiation Facility, for assistance during data collection. This work is supported by the National Natural Science Foundation of China Grants

performed the sample preparation, biochemistry and crystallization experiments. Xu.L. collected the diffraction data and solved the structure with the help from X

performed the Molecular dynamics analysis

TRIM family proteins: roles in autophagy, immunity, and carcinogenesis

To TRIM or not to TRIM: the balance of host-virus interactions mediated by the ubiquitin system

The tripartite motif family identifies cell compartments

Structure and function of the SPRY/B30. 2 domain proteins involved in innate immunity

TRIM proteins and their roles in antiviral host defenses

GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscle

The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1 activation by Ras signalling

Tripartite motif-containing protein 7 regulates hepatocellular carcinoma cell proliferation via the DUSP6/p38 pathway

TRIM7 inhibits enterovirus replication and promotes emergence of a viral variant with increased pathogenicity

Identification of antinorovirus genes in human cells using genomewide CRISPR activation screening

Crystal structure and mutational analysis of the human TRIM7 B30. 2 domain provide insights into the molecular basis of its binding to glycogenin-1

Human norovirus proteins: implications in the replicative cycle, pathogenesis, and the host immune response

Human Norovirus NTPase Antagonizes Interferon-β Production by Interacting With IkB Kinase ε

Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV

Evasion of type I interferon by SARS-CoV-2

SARS-CoV-2 Nsp5 demonstrates two distinct mechanisms targeting RIG-I and MAVS To evade the innate immune response

SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules

SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon

Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2

SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses

N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1

Structure-function analysis of GNIP, the glycogenin-interacting protein

RNF90 negatively regulates cellular antiviral responses by targeting MITA for degradation

Tripartite Motif Containing 11 Interacts with DUSP6 to Promote the Growth of Human Osteosarcoma Cells through Regulating ERK1/2 Pathway

Negative Regulation of RNF90 on RNA Virus-Triggered Antiviral Immune Responses Targeting MAVS

TRIM7 promotes proliferation and migration of vascular smooth muscle cells in atherosclerosis through activating c-Jun/AP-1

The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein

COSMIC: the catalogue of somatic mutations in cancer

Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways

Structural characterization of SARS-CoV-2: Where we are, and where we need to be

Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex

SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12)

Discovery of COVID-19 inhibitors targeting the SARS-CoV-2 Nsp13 helicase. The journal of physical chemistry letters 11

E3 ubiquitin ligase tripartite motif 7 positively regulates the TLR4-mediated immune response via its E3 ligase domain in macrophages

Envelope protein ubiquitination drives entry and pathogenesis of Zika virus

3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses

Cleavage map and proteolytic processing of the murine norovirus nonstructural polyprotein in infected cells

Biosynthesis, purification, and characterization of the human coronavirus 229E 3C-like proteinase

Mechanisms and enzymes involved in SARS coronavirus genome expression

N-degron and C-degron pathways of protein degradation

The eukaryotic proteome is shaped by E3 ubiquitin ligases targeting Cterminal degrons

C-terminal end-directed protein elimination by CRL2 ubiquitin ligases

SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model

The protein complex crystallography beamline (BL19U1) at the Shanghai Synchrotron Radiation Facility

CCP4i2: the new graphical user interface to the CCP4 program suite

PHENIX: building new software for automated crystallographic structure determination

Towards automated crystallographic structure refinement with phenix. refine

ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB

Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes

PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data

position) of 2C is colored in green. b, Replacement or manipulation of Q329 at -1 position blocked TRIM7 binding, as revealed by the ITC measurements. c, MD simulation of Q329E mutation for TRIM7-2C complex formation. d, The pocket in TRIM7 accommodating F328 (-2 position) and L327 (-3 position) of 2C. e, ITC measurements of 2C mutants at the -2 position, to TRIM7. f, Integrated heat plots for ITC measurements of TRIM7

HA, TRIM7 catalytic dead mutant (C29A/C31A)

Flag-NTPase or empty vector was co-transfected with Ubi-Myc in the presence or absence of TRIM7-HA in HEK293T cells. f, TRIM7 promoted the NTPase degradation in a dose-dependent fashion. Cellular degradation assays in cells expressing the TRIM7 and NTPase proteins indicated. Cells were treated with DMSO or MG132. Mut, TRIM7 catalytic dead mutant. g, IFN-β reporter assay. HEK293T cells were transfected with an IFN-β promoter-driven luciferase reporter construct, a RIG-I CARD expression plasmid and the indicated NTPase expression plasmid in the presence or absence of TRIM7. Relative luciferase activity was quantified 24 h post-transfection. Error bars represent mean ± SEM of technical triplicates. Statistical significance was determined by comparing each respective "RIG-I 2C + Vector" group using two-way ANOVA

Cells were treated with DMSO or MG132. Mut, TRIM7 catalytic dead mutant. g-h, Overall structures of TRIM7 in complex with NSP5 (residues 300-306) (g) or NSP8 (residues 194-198) (h). i, IFN-β stimulation determined by a luciferase reporter. HEK293T cells were transfected with a luciferase reporter plasmid under the control of the IFN-β promoter, a RIG-I CARD plasmid and the indicated NSP proteins expression plasmid along with or without the TRIM7 expression plasmid

Error bars represent mean ± SEM of technical triplicates. Statistical significance was determined by comparing each respective "RIG-I 2C + Vector" group using two-way ANOVA with Dunnett's correction

We thank all the members of Zhang Lab for their kind help. We thank Dr. Jian Lei for supporting plasmids encoding SARS-CoV-2 proteins. We thank the staffs from

The authors declare no competing interests.